Abstract
A phase I study indicates that the combination of utomilumab, an investigational antibody that binds CD137, plus pembrolizumab is safe and well tolerated, yielding sustained responses in patients with various solid cancers.
©2016 American Association for Cancer Research.
MeSH terms
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Humans
-
Neoplasms / drug therapy*
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Survival Analysis
-
Treatment Outcome
-
Tumor Necrosis Factor Receptor Superfamily, Member 9 / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
Tumor Necrosis Factor Receptor Superfamily, Member 9
-
pembrolizumab